Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company is headquartered in Toronto, Canada.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-1.51M |
| EBITDA | $-35.82M |
| Operating Margin | 0.00% |
| Return on Equity | -70.50% |
| Return on Assets | -41.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.39 |
| Price-to-Book | 2.84 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 4.75 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $20.83M |
| Float | $17.63M |
| % Insiders | 6.37% |
| % Institutions | 49.70% |
Volatility is currently contracting
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MSLE and any ticker you trade — then tracks every position and per-strategy win rate.